^
    Back
    Association details:
    Biomarker:TNFAIP3 overexpression + BRAF mutation
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cell Death Dis
    Title:

    A20 promotes melanoma progression via the activation of Akt pathway

    Published date:
    09/23/2020
    Excerpt:
    A20 suppression significantly increased the sensitivity of A375RS and A2058RS cells to Vemurafenib treatment revealed by the CCK8 assay...the up-regulation of A20 conferred the acquired resistance to Vemurafenib in BRAF-mutant melanoma...
    DOI:
    10.1038/s41419-020-03001-y